Moreover, the frameshift mutations in nucleophosmin 1 (NPM1), a genetic event in about one-third of patients with acute myeloid leukemia (AML), lead to increased Akt activation that renders hypersensitivity to Akt inhibitors [257]. This evidence concerns the gene AKT1 and acute myeloid leukemia.